ACS chemical neuroscience molecule spotlight on potiga (Ezogabine)

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

On June 10th, 2011, the U.S. Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals.

Original languageEnglish (US)
Number of pages1
JournalACS Chemical Neuroscience
Volume3
Issue number8
DOIs
StatePublished - Aug 15 2012

Fingerprint

Neurosciences
Molecules
United States Food and Drug Administration
Seizures
Pharmaceutical Preparations
ezogabine

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on potiga (Ezogabine). / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 3, No. 8, 15.08.2012.

Research output: Contribution to journalReview article

@article{95901adf226c4ba3917a28c057c6030c,
title = "ACS chemical neuroscience molecule spotlight on potiga (Ezogabine)",
abstract = "On June 10th, 2011, the U.S. Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals.",
author = "Hopkins, {Corey R.}",
year = "2012",
month = "8",
day = "15",
doi = "10.1021/cn3000789",
language = "English (US)",
volume = "3",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on potiga (Ezogabine)

AU - Hopkins, Corey R.

PY - 2012/8/15

Y1 - 2012/8/15

N2 - On June 10th, 2011, the U.S. Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals.

AB - On June 10th, 2011, the U.S. Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals.

UR - http://www.scopus.com/inward/record.url?scp=84865106671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865106671&partnerID=8YFLogxK

U2 - 10.1021/cn3000789

DO - 10.1021/cn3000789

M3 - Review article

C2 - 22896808

AN - SCOPUS:84865106671

VL - 3

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 8

ER -